Elekta Announces Installation of Leksell Gamma Knife(R) Perfexion(TM) at Haukeland University Hospital in Norway
Posted on: Monday, 20 October 2008, 12:00 CDT
Regulatory News:
Elekta (STO:EKTAB):
Haukeland University Hospital in Bergen, Norway installs the latest technology for treatment of brain disorders.
Leksell Gamma Knife(R) Perfexion(TM) is the latest and most advanced solution on the market for non-invasive treatment of brain disorders. This new generation Leksell Gamma Knife is fully automated and has the ability to treat patients with multiple brain metastases in much shorter times compared to other technologies.
Gamma Knife(R) surgery is used to manage numerous neurosurgical conditions, including brain tumors such as metastatic cancer, as well as vascular malformations and certain functional disorders. This unmatched method provides pinpoint accuracy, is highly efficient and produces outstanding results. Patients benefit from fast, painless treatment, often conducted in an outpatient surgical setting without the need for general anesthesia or even convalescence. To date, over 500,000 patients world wide have undergone Gamma Knife surgery.
"Leksell Gamma Knife Perfexion technology represents a major advance in brain radiosurgery," says Olof Sanden, Executive Vice President, Elekta Europe, Africa & Latin America. "It also offers enormous opportunities to treat lesions all over the brain in a single treatment, while also ensuring excellent patient comfort" he says. "We are pleased to see the considerable interest in the new system, among both old and new users. Leksell Gamma Knife Perfexion was introduced two years ago and today we have already installed around 30 systems around the world", Olof Sanden says.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
This information was brought to you by Cision http://www.cisionwire.com
Source: Business Wire
Related Articles
- Northstar Neuroscience Receives FDA Approval for a Clinical Study of Its Cortical Stimulation System for the Treatment of Major Depressive Disorder
- European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
- FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
- FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
- Carondelet Health Network Selects Patient Care Technology Systems' Automatic Tracking Software; Software Will Track Patients and Mobile Medical Equipment in Emergency Department and Operating Rooms
- Pfizer's Lyrica Approved for the Treatment of Generalized Anxiety Disorder (GAD) in Europe
- Predictors of Disorientation Among Brain Injury and Stroke Patients During Rehabilitation
- Hoag Memorial Hospital Presbyterian Selects Patient Care Technology Systems' Emergency Department Information System
- Christiana Care Selects Patient Care Technology Systems' Passive Tracking Software for Wilmington Hospital Emergency Department
- "We Just Feel so Blessed" BR Boy First to Get New Drug Treatment for Rare Genetic Disorder
 |
 |
User Comments (0)
RSS Feeds